期刊
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
卷 56, 期 4, 页码 2173-2177出版社
AMER SOC MICROBIOLOGY
DOI: 10.1128/AAC.05913-11
关键词
-
资金
- National Institute of Allergy and Infectious Diseases (NIAID) (DMID) [10-0065]
Ertapenem is active against extended-spectrum-beta-lactamase (ESBL)-producing Enterobacteriaceae organisms but inactive against Pseudomonas aeruginosa and Acinetobacter baumannii. Due to a lack of therapeutic data for ertapenem in the treatment of ESBL bloodstream infections (BSIs), group 2 carbapenems (e.g., imipenem or meropenem) are often preferred for treatment of ESBL-producing Enterobacteriaceae, although their antipseudomonal activity is unnecessary. From 2005 to 2010, 261 patients with ESBL BSIs were analyzed. Outcomes were equivalent between patients treated with ertapenem and those treated with group 2 carbapenems (mortality rates of 6% and 18%, respectively; P = 0.18).
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据